1. Bilezikian JP, Khan AA, Potts JT Jr on behalf of the Third International Workshop on the Management of Asymptomatic Primary Hyperthyroidism. Guidelines for the Management of Asymptomatic Primary Hyperparathyroidism: Summary Statement from the Third International Workshop. J Clin Endocrinol Metab 2009;94:335-339;
2. Khan AA, Bilezikian JP, Potts JT Jr, The Diagnosis and Management of Asymptomatic Primary Hyperparathyroidism Revisited. J Clin Endocrinol Metab 2009;94:333-334.
3. Eastell R, Arnold A, Brandi ML, Brown EM, D'Amour P, Hanley DA, Sudhaker Rao D, Rubin MR, Goltzman D, Silverberg SJ, Marx SJ, Peacock M, L. Mosekilde L, Bouillon R, Lewiecki EM. Diagnosis of Asymptomatic Primary Hyperparathyroidism: Proceedings of the Third International Workshop. J Clin Endocrinol Metab. 2009’94:340-350.
4. Silverberg SJ, Lewiecki EM, Mosekilde L, Peacock M, Rubin MR.  Presentation of Asymptomatic Primary Hyperparathyroidism: Proceedings of the Third International Workshop. J Clin Endocrinol Metab 2009;94:351-365.
5. Udelsman R, Pasieka JL, Sturgeon C, Young JEM, Clark OH. Surgery for Asymptomatic Primary Hyperparathyroidism: Proceedings of the Third International Workshop. J Clin Endocrinol Metab 2009;94:366-372.
6. Khan A, Grey A, Shoback D.Medical Management of Asymptomatic Primary Hyperparathyroidism: Proceedings of the Third International Workshop. J Clin Endocrinol Metab 2009;94:373-381.
7. Brossard J-H, Lepage R, Cardinal H, Roy L, Rousseau L, Dorias C, d’Amour P. Influence of glomerular filtration rate on non-(1-84) parathyroid hormone (PTH) detected by intact PTH assays. Clin chem. 2000;46:697-703.
8. D’Amour P, Brossard J-H, Rousseau L. et al. Structure of non-(1-84) fragments secreted by parathyroid glands in primary and secondary hyperparathyroidism. Kidney Int. 2005;68:998-1007.
9. Bilezikian JP, Silverberg SJ, Rubin M, Potts, Jr. JT: Asymptomatic primary hyperparathyroidism: present management and future options. IN: Clinical Cases in Bone and Mineral Metabolism 2006;3:132-140.
10. Gao P, Scheibel S, D’Amour P, John M, Rao S, Schmidt-Gayk H, Cantor T. Development of a novel immunoradiometric assy exclusively for biologically active whole parathyroid hormone 1-84: implications for improvement of accurate assessment of parathyroid function. J Bone Min Res 2001;16:605-614.
11. John MR, Goodman WG, Gao P, Cantor T, Salusky IB, Juppner H. A novel immunoradiometric assay detects full-length human PTH but not amino-terminally truncated fragements; implications for PTH measurement in renal failure. J Clin Endocrinol Metab. 1999;84:4287-4290.
12. Silverberg SJ, Brown I, LoGerfo P, Gao P, Cantor T, Bilezikian JP: Clinical utility of an immunoradiometric assay for whole PTH (1-84) in primary hyperparathyroidism. J Clin Endocrinol Metab 2003;88:4725-4730.
13. Carnevale V, Dionisi S, Nofroni I et al. Potential clinical utility of a new IRMA for parathyroid hormone in postmenopausal patients with primary hyperparathyroidism. Clin Chem 2004;50:626-631.
14. Boudou P, Ibrahim F, Cormier C, Chabas A, Sarfati E, Souberbielle JC. Third- or second-generation parathyroid hormone assays: a remaining debate in the diagnosis of primary hyperparathyroidism. J Clin Endocrinol Metab 2005;90:6370-6372.
15. Wesseling K, Coburn JW, Salusky IB. The renal osteodystrophies. In: DeGroot LJ, Jameson JL eds. Endocrinology, vol 2. 5th ed. Philadelphia: Elsevier Saunders;2006;1697-1718.
16. Szalat A, Mazeh H, Freund HR. Lithium-associated hyperparathyroidism: report of 4 cases and review of the literature. Eur J Endocrinol 2009;160:317-23.
17. Arnold A, Brown MF, Urena P, Randall, RG, Sarfati E, Drueke TB: Monoclonality of parathyroid tumors in chronic renal failure and in primary parathyroid hyperplasia. J Clin Investig 1995;95:2047-2053.
18. Fuleihan GE, Brown EM, Heath HH III. Familial benign hypocalciuric hypercalcemia and neonatal primary hyperparathyroidism. In: Principles of Bone Biology, 3rd Edition (Bilezikian JP, Raisz LG, Martin TJ, eds) Academic Press, San Diego, 2008:1327-1345
19. Brown EM. Clinical lessons from the calcium-sensing receptor. Nat Clin Pract Endocrinol Metab 2007;3:122-133.
20. Arnold A. Molecular basis of primary hyperparathyroidism. In: Bilezikian JP, Marcus R, Levine MA eds. The Parathyroids, 2nd edition, 2001. San Diego, Academic Press, 331-347.
21   Silverberg SJ, Bilezikian JP: “Incipient” primary hyperparathyroidism: a “forme fruste” of an old disease. J Clin Endocrinol Metab 88:5348-5352, 2003.
22. Rosen CJ. Clinical Practice. Vitamin D insufficiency.N Eng J Med 2011;364:248-254.
23. Lundgren E, Rastad J, Thrufjell E, Akerstrom G, Ljunghall S. Population-based screening for primary hyperparathyroidism with serum calcium and parathyroid hormone values in menopausal women. Surgery 1997;121:287–94.
24. Lundgren E, Hagstrom EG, Lundin J, Winnerback K, Roos J, Ljunghall S, et al. Primary hyperparathyroidism revisited in menopausal women with serum calcium in the upper normal range at population-based screening 8 years ago. World J Surg 2002;26:931–6.
25. Lowe H, McMahon DJ, Rubin MR, Bilezikian JP, Silverberg SJ: Normocalcemic primary
hyperparathyroidism: further characterization of a new clinical phenotype. J Clin Endocrinol Metab.
2007;92(8):3001-3005.
26. Maruani G, Hertig A, Paillard M, Houillier P. Normocalcemic primary hyperparathyroidism: evidence for a generalized target-tissue resistance to parathyroid hormone. J Clin Endocrinol Metab 2003;88:4641–8.
27.Tordjman KM, Greenman Y, Osher E, Shenkerman G, Stern N. Characterization of normocalcemic primary hyperparathyroidism. Am J Med 2004;117:861–3.
28. Bilezikian JP Silverberg SJ. Normocalcemic Primary Hyperparathyroidism. Brazilian Archives of Endocrinology and Metabolism 2010;54:106-109.
29. Heath H III, Hodgson SF, Kennedy M: Primary hyperparathyroidism: incidence, morbidity and potential economic impact in a community. N Engl J Med 1980;302:189-193.
30. Cope O: The story of hyperparathyroidism at the Massachusetts General Hospital. N Engl J Med 1966;21(1):174-182.
31. Keating FR Jr, Cook EN: Recognition of primary hyperparathyroidism: analysis of 24 cases. Am Med Assoc 1945;129:994-1002.
32. Wermers RA, Khosla S, Atkinson EJ, et al. Incidence of primary hyperparathyroidism in Rochester, Minnesota, 1993-2001: an update on the changing epidemiology of the disease. J Bone Miner Res 2006;21:171-7.
33. Stenstrom G, Heedman P: Clinical findings in patients with hypercalcemia: a final investigation based on biochemical screening. Acta Med Scand 1974;195:473-477.
34. Rastad J, Lundgren E, Ljunghall S: Clinical presentation of primary hyperparathyroidism. In: The Parathyroids, 2nd Edition (Bilezikian JP, Marcus R, Levine MA, eds), Academic Press, San Diego, CA 2001;361-374.
35. Palmer M, Jacobsson G, Akerstrom G, Ljunghall S: Prevalence of hypercalcemia in a health survey: A 14-year follow-up study of serum calcium values. Eur J Clin Invest 1988;18:39-46.
36. Christensson T, Hellstrom K, Wengle B, Alveryd A, Wikland B: Prevalence of hypercalcemia in a health screening in Stockholm. Acta Med Scand 1976;200:131-137.
37. Akerstrom G, Rudberg C, Grimelius L, Bergstrom R, Johansson H, Ljunghall S, Rastad J: Histologic parathyroid abnormalities in an autopsy series. Hum Pathol 1986;17:520-527.
38. Lundgren E, Rastad J, Thurfjell E, Akerstrom G, Ljunghall S: Population-based screening for primary hyperparathyroidism with serum calcium and parathyroid hormone values in menopausal women. Surgery 1997;121:287-294.
39. Lundgren E: Primary hyperparathyroidism of postmenopausal females. Prospective case-control analysis on prevalence, clinical characteristics and treatment. Compr Sum Ups Fac Med 1999;820:1-51.
40. Wermers RA, Khosla S, Atkinson EJ, Hodgson SF, O’Fallon WM, Melton III LJ: The rise and fall of primary hyperparathyroidism: A population-based study in Rochester, Minnesota, 1965-1992. Ann Intern Med 1997;126:433-440.
41. Cohen J, Gierlowski TC, Schneider AB: A prospective study of hyperparathyroidism in individuals exposed to radiation in childhood. JAMA 1990;264:581-584.
42 Bondeson AG, Bondeson L, Thompson NW: Hyperparathyroidism after treatment with radioactive iodine: not only a coincidence? Surgery 1989;106:1025-1027.
43. Brandi ML, Gagel RF, Angeli A et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Meta 2001;86:5658-5671.
44.  Bilezikian JP, Brandi ML, Rubin M, Silverberg SJ: Primary hyperparathyroidism: new concepts in clinical, densitometric, and biochemical features. J Int Med, 2005;257:6-17.
45. Brandi ML, Gagel RF, Angeli A, Bilezikian JP et. Al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001;86:5658-5671.
46. Pellegata NS, Quintanilla-Martinez L, Siggelkow H et al. Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans. Proc Nat Acad Sci USA; 2006;103:15558-15563.
47. Georgitsi M, Raitila A, Karhu A, et al. Germline CDKN1B/p27Kip1 mutation in multiple endocrine neoplasia. J Clin Endocrinol Metab 2007;92:3321-3325.
48. Simonds WF, James-Newton LA, Agarwal SK et al. Familial isolated hyperparathyroidism : clinical and genetic characteristics of 36 kindreds. Medicine (Baltimore) 2002;81:1-26.
49. Marx SJ, Simonds SF, Agarwal SK et al. Hyperparathyroidism in hereditary syndromes: special expressions and special managements. J Bone Min Res 2002;17(suppl 2): N37-43.
50. Shattuck TM, Valimaki S, Obara T, et al. Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma. N Engl J Med 2003;349:1722-1729.
51. Simonds WF, Robbins CM, Agarwal SK, Hendy GN, Carpten JD, Marx SJ Familial isolated hyperparathyroidism is rarely caused by germline mutation in HRPT2, the gene for the hyperparathyroidism-jaw tumor syndrome. J Clin Endocrinol Metab 2004;89:96-102.
52. Marx SJ.  Hyperparathyroid genes: sequences reveal answers and questions. Endocr Pract 2011;17:Suppl3:18-27
53. Arnold A.  Familial hyperparathyroidism. In: Rosen CJ, ed.  Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 7th edition.  Washington, DC: American Society for Bone and Mineral Research, 2008:361-367.
54. Marcocci C, Cetani F, Rubin MR, Silverberg SJ, Pinchera A, Bilezikian JP. Parathyroid Carcinoma. J Bone Miner Res 2008;23:1869-1880. .
55. Brown EM. Four parameter model of the sigmoidal relationship between parathyroid hormone release and extracellular calcium concentration in normal and abnormal parathyroid tissue. J Clin Endocrinol Metab 1983;56:572-581
56. Mallya SM, Gallagher JJ, Wild YK, et al. Abnormal parathyroid cell proliferation precedes biochemical abnormalities in a mouse model of primary hyperparathyroidism. Mol Endocrinol 2005; 19:2603-9.
57. Arnold A. et al. Molecular pathogenesis of primary hyperparathyroidism. J Bone Min Res 2002;17 (suppl 2): N30-N36.
58. Arnold A, Kim HG, Gaz RD et al. Molecular cloning and chromosomal mapping of DNA rearranged with the parathyroid hormone gene in a parathyroid adenoma. J Clin Invest 1989;83:2034-2040.
59. Hemmer S, Wasenius VM, Haglund C et al. Deletion of 11q23 and cyclin D1 overexpression are frequent aberrations in parathyroid adenomas. Am J Path 2001;158:1355-1362.
60. Tominaa Y, Tsuzuki T, Uchinda K et al. Expression of PRAD1/cyclin D1, retinoblastoma gene products, and Ki67 in parathyroid hyperplasia caused by chronic renal failure versus primary adenoma. Kidney Int 1999;55:1375-1383.
61. Chandrasekharappa SC, Guru SC, Manickam P et al. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 1997;276:404-407.
62. European consortium on MEN1. identification of the multiple endocrine neoplasia type 1 (MEN1) gene. Hum Mol Genet 1997;6:1177-1183.
63. Carling T, Correa P, Hessman O et al. Parathyroid MEN1 gene mutations in relation to clinical characteristics of nonfamilial primary hyperparathyroidism. J Clin Endocrinol Metab 1998;83:2960-2963.
64. Krebs LJ et al. HRPT2 mutational analysis of typical sporadic parathyroid adenomas. J Clin Endocrinol Metab 2005;90:5015-5017.
65. Howell VM, Cardinal JW, Richardson AL, Gimm O, Robinson BG, Marsh DJ. Rapid mutation screening for HRPT2 and MEN1 mutations associated with familial and sporadic primary hyperparathyroidism. J Mol Diagn. 2006 Nov;8(5):559-66.
66. Mizusawa N, Uchino S, Iwata T, Tsuyuguchi M, Suzuki Y, Mizukoshi T, Yamashita Y, Sakurai A, Suzuki S, Beniko M, Tahara H, Fujisawa M, Kamata N, Fujisawa K, Yashiro T, Nagao D, Golam HM, Sano T, Noguchi S, Yoshimoto K. Genetic analyses in patients with familial isolated hyperparathyroidism and hyperparathyroidism-jaw tumour syndrome.Clin Endocrinol (Oxf). 2006 Jul;65(1):9-16.
67. Tahara H, Smith AP, Gas RD et al. Genomic localization of novel candidate tumor suppressor gene loci in human parathyroid adenomas. Cancer Res 1996;56:599-605.
68. Palanisamy N, Imanishi Y, Rao PH et al. Novel chromosomal abnormalities identified by comparative genomic hybridization in parathyroid adenomas. J Clin Endocrinol Metab 1998;83:1766-1770.
69. Farnebo F, Kytola S, The BT et al. Alternative genetic pathways in parathyroid tumorigenesis. J Clin Endocrinol Metab 1999;84:3775-3780.
70. Bjorklun P, Kerstrom G, Westin G. Activated beta-catenin in the novel human parathyroid tumor cell line sHPT-1.Biochem Biophys Res Commun. 2007352(2):532-6. 
71.Verdonk CA, Edis AJ:  Parathyroid "double adenomas": fact or fiction?  Surgery  1981;90:523-526.
72. Harness JK, Ramsburg Sr, Nishiyama RH, Thompson NW:  Multiple adenomas of the parathyroids: do they exist?  Arch Surg 1979;114:468-474.
73. Attie JN, Bock G, Auguste L:  Multiple parathyroid adenomas: report of thirty-three cases.  Surgery 1990;108:1014-102.
74. Silverberg SJ, Bilezikian JP: Primary hyperparathyroidism. In: Endocrinology, Sixth Edition, (DeGroot LJ, Jameson JL, eds) Potts JT, Section Editor, Saunders-Elsevier, Philadelphia, 1176-1197, 2010.
75. Bilezikian JP: Nephrolithiasis in primary hyperparathyroidism. In: Kidney Stones: Medical and Surgical Treatment (Coe FL, Favus MJ, Pak CYC, Parks JH, Preminger GM, eds) Lippincott-Raven, Philadelphia, 1996;783-802.
76. Bilezikian JP, Silverberg SJ, Shane E, Parisien M, Dempster DW: Characterization and evaluation of asymptomatic primary hyperparathyroidism. J Bone Mineral Res 1991;6(Suppl I):585-589.
77. Bilezikian JP: Primary hyperparathyroidism. In: www.ENDOTEXT.org (Version of April 01, 2011) DeGroot L, Editor; Singer F, Section Editor; (MDTEXT.COM, Inc, S. Dartmouth, MA), 2009.
78. Marcocci C, Getani F. Primary Hyperparathyroidism. N Eng J Med 2011;365:2389-2397
79. Silverberg SJ, Shane E, DeLaCruz L, et al. Skeletal disease in primary hyperparathyroidism. J Bone Mineral Res 1989;4:283-291.
80. Miller PD, Bilezikian JP: Bone densitometry in asymptomatic primary hyperparathyroidism. J Bone Min Res 2002;17 (Suppl 2) N98-N102.
81. Silverberg SJ, Bilezikian JP: Primary hyperparathyroidism. IN: Oxford Textbook of Endocrinology and Diabetes, 2nd Edition, (Wass JAH, Stewart PM, eds) Oxford University Press, Oxford, England, 653-664, 2011.
82. Hock JM, Canalis JM, Raisz LG.  Parathyroid hormone: anabolic and catabolic
on bone and interactions with growth factors.  In Bilezikian, JP (ed.).  The Parathyroids: Basic and Clinical Concepts. San Diego, Academic Press, 2001: 183-198.
83. Beck HS, Jensen JE, Rasmussen L, Hauge EM, Brixen K. Effects on bone geometry, density and microarchitecture in the distal radius but not the tibia in women with primary hyperparathyroidism: a case-control study using HR-pQCT. J Bone Miner Res 2010;25:`941-1947.
84. Cohen A, Dempster DW, Muller R, Guo XE, Nickolas TL, Liu XS, Zhang XH, Wirth AJ, van Lenthe GH, Kohler T, McMahon DJ, Zhou H, Rubin MR, Bilezikian JP, Lappe JM, Recker RR, Shane E: Assessment of trabecular and cortical architecture and mechanical competence of bone by transilial bone biopsy: comparison with high-resolution peripheral computed tomography. Osteoporosis Int’l 2010;21:263-273.
85. Rubin MR, Bilezikian JP: Parathyroid hormone as an anabolic therapy.  Drugs, 2005;65:2481-2498.
86. Bilezikian JP: Clinical use of parathyroid hormone in osteoporosis. IN: Osteoporosis – Pathophysiology and Clinical Management, 2nd Edition (Adler RA, ed), Humana Press, 2010;511-526.
87. Silva BC, Bilezikian JP: New approaches to the treatment of osteoporosis.  Ann Rev Med, 2011;62:307-322.
88. Silverberg SJ, Locker FG, Bilezikian JP.  Vertebral osteopenia: a new indication for surgery in primary hyperparathyroidism.  J Clin Endocrinol Metab 1996;81: 4007-4012.
89. Parisien M, Silverberg SJ, Shane E, et al.  The histormorphometry of   bone in primary hyperparathyroidism:  preservation of cancellous bone structure.  J Clin Endocrinol Metab 1990;70:930-938.
90. Parisien M, Silverberg SJ, Shane E, de la Cruz L, Lindsay R, Bilezikian JP and Dempster DW.
The histomorphometry of bone in primary hyperparathyroidism: preservation of cancellous bone. J Clin Endocrinol Metab 1990;70: 930-938.
91. Dempster DW, Parisien M, Silverberg SJ, Liang X-G, Schnitzer M, Shen V, Shane E, Kimmel DB, Recker R, Lindsay R, Bilezikian JP.  On the mechanism of cancellous bone preservation in postmenopausal women with mild primary hyperparathyroidism. J Clin Endocrinol Metab 1999;84:1562-1566.
92. Roschger R, Dempster DW, Zhou H, Paschalis EP, Silverberg SJ, Shane E, Bilezikian JP,
Klaushofer K. New observations on bone quality in mild primary hyperparathyroidism as
determined by quantitative backscattered electron imaging. J Bone Min Res 2007;22:717-723.
93. Dempster DW, Müller R, Zhou H, Kohler T, Shane E, Parisien M, Silverberg SJ, Bilezikian JP:
Preserved three-dimensional cancellous bone structure in mild primary hyperparathyroidism. Bone
2007;41:19-24.
94. Dauphine RT, Riggs BL, Scholz DA: Back pain and vertebral crush fractures: an unrecognized mode of presentation for primary hyperparathyroidism. Ann Intern Med 1975;83:365-367.
95. Khosla S, Melton LJ III, Wermers RA, Crowson CS, O’Fallon WM, Riggs BL: Primary hyperparathyroidism and the risk of fracture: a population based study. J Bone Min Res 1999;14:1700-1707.
96. Rao DS, Ellis B, Kleerekoper M, Parfitt AM: Mild asymptomatic primary hyperparathyroidism is not a risk factor for vertebral fractures. Ann Intern Med 1988;109:959-962.
97. Melton LJ III, Atkinson EJ, O’Fallon WM, Heath H III: Risk of age-related fractures in patients with primary hyperparathyroidism. Arch Intern Med 1992;152:2269-2273.
98. Kleerekoper M, Peterson E, Nelson D, et al. Identification of women at risk for developing postmenopausal osteoporosis with vertebral compression fractures: role of history and single photon absorptiometry. Bone Mineral 1989;7:171-186.
99. Vignali E, Viccica G, Diacinti D, Cetani F, Cianferotti L, Ambrogini E, Banti C, Del Fiacco R, Bilezikian JP, Pinchera A, Marcocci C: Morphometic vertebral fractures in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab 2009;94:2306-2312.
100. Seeman E. Bone Quality—the material and structural basis of bone strength.J Bone Miner Res 2008;26:1-8.
101. Chen Q, Kaji H, Iu M-F, Nomur R, Sowa H, Yamauchi M, Tsukamoto T, Sugimoto T, Chihara K. Effects of an excess and a deficiency of endogenous parathyroid hormone on volumetric bone mineral density and bone geometry determined by peripheral quantitative computed tomography in female subjects. J Clin Endocrinol Metab 2003;88:4655-4658.
102. Parfitt AM, Parathyroid hormone and periosteal bone expansion. J Bone Miner Res 2002;17:1741-1743.
103. Bilezikian JP. Bone strength in primary hyperparathyroidism. Osteoporosis Int. 2003;14(Suppl 5):5113-5117.
104. Silverberg SJ, Shane E, Jacobs TP, Siris E, Bilesikian JP.  A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. N Engl J Med 1999;341:1249-1255.
105. Rubin MR, Bilezikian JP, McMahon DJ, et al. The Natural History of Primary Hyperparathyroidism With or Without Parathyroid Surgery after 15 Years. J Clin Endocrinol Metab 2008;93:3462-3470.
106. Tamura Y, Araki A, Chiba Y. et al. Remarkable increase in lumbar spine bone mineral density and amelioration in biochemical markers of bone turnover after parathyroidectomy in elderly patients with primary hyperparathyroidism: a 5-year follow-up study.  J Bone Miner Metab 2007;25:226-231.
107. Sitges-Serra A, Garcia L, Prieto R, Perla MJ, Nogues X, Sancho JJ. Effect of parathyroidectomy for primary hyperparathyroidism on bone mineral density in postmenopausal women. Br J Surg 2010;97;1012-1019.
108. Sankaran S, Gamble G, Bolland M, Reid IR, and Grey A. Skeletal effects of interventions in mild primary hyperparathyroidism: a meta-analysis. J Clin Endocrinol Metab 2010;95:1653-1662.
109. Vestergaard P, Mosekilde L 2004 Parathyroid surgery is associated with a decreased risk of hip and upper arm fractures in primary hyperparathyroidism: a controlled cohort study. Ann Int Med 2004;255:108-114.
110. Rejnmark L, Vestergaard P, Mosekilde L. Nepholithiasis and renal calcifications in primary hyperparathyroidism. J Clin Endocrinol Metab 2011;96:2377-2385
111. Scillitani A, Guarnieri V, Battista C et al. Primary hyperparathyroidism and the presence of kidney stones are associated with different haplotypes of the calcium-sensing receptor. J Clin Endocrinol Metab 2007;92:277-283.
112. Odvina CV, Sakhaee K, Heller HJ. et al.Biochemical characterization of primary hyperparathyroidism with and without kidney stones.  Urol Res 2007;35:123-128.
113. Bilezikian JP, Potts JT, Fuleihan Gel-H, Kleerekoper M, Neer R, Peacock M, Rastad J, Silverberg SJ, Udelsman R, Wells SA Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century. J Bone Miner Res 17(Suppl 2):N2–N11, and J Clin Endocrinol Metab 2002;87:5353–5361.
114. National Kidney Foundation K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003;42:S1-S200.
115. Kidney Disease: Improving Global Outcomes (KIDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl 2009;113:S1-S130.
116. Gault MH, Longerich LL, Harnett JD, Wesolowski C 1992 Predicting glomerular function from adjusted serum creatinine. Nephron 1992;62:249-256.
117. Levey AS, Bosch JP, Lewis JB et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461-470.
118. Walker MD, Dempster D, McMahon DJ, Udesky J, Shane E, Bilezikian JP, Silverberg SJ.  Effect of renal function on skeletal health in primary hyperparathyroidism. J Clin Endocrinol Metab. 2012 (In Press)
119 Procopio M, Borretta G. Derangement of glucose metabolism in hyperparathyroidism. J Endocrinol Invest 2003;11:17-35.
120. Taylor WH, Khaeeli AA. Coincident diabetes mellitus and primary hyperparathyroidism. Diabetes Metab Res Rev 2001;17:175-180.
121. Procopio M, Magro G, Cesario F, Piovesan A, Pia A, Molineri N, Borretta G. The oral glucose tolerance test reveals a high frequency of both impaired glucose tolerance and undiagnosed Type 2 diabetes mellitus in primary hyperparathyroidism. Diabet Med 2002 19:958-961.
122. Marx S. Multiple Endocrine Neoplasia, type 1. In Bilezikan (ed) : The Parathyroids. New York, Academic Press. 2001, 535-584.
123. Brandi ML, Gagel FR,  Angeli A: Consensus guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001;86:5658-5671.
124. Sitges-Serra A, Alonso M, deLecea C, Gores PF, Sutherland DE: Pancreatitis and hyperparathyroidism. Br J Surg 1988;75:158-160.
125. Prinz RA, Aranha GV: The association of primary hyperparathyroidism and pancreatitis. Am Surg 1985;51:325-329.
126. Bess MA, Edis AJ, van Heerden JA. Hyperparathyroidism and pancreatitis. Chance or a causal association. JAMA 1980;243:246-247.
127. Khoo TK, Vege SS, Abu-Lebdeh HS, Ryu E, Nadeem S, Wermers RA. Acute pancreatitis in primary hyperparathyroidism: a population-based study. J Clin Endocrinol Metab 2009;94:2115-2118
128. Patten BM, Bilezikian JP, Mallette LE et al. The neuromuscular disease of hyperparathyroidism. Ann Inter Med 1974;80:182-194.
129. Turken SA, Cafferty M, Silverberg SJ, et al. Neuromuscular involvement in mild, asymptomatic primary hyperparathyroidism. Am J Med 1989;87:553-557.
130.Ljunghall S, Jakobsson S, Joborn C, Palmer M, Rastad J, Akerstrom G.  1991.  Longitudinal studies of mild primary hyperparathyroidism.  J Bone Mineral Res 1991;6(Suppl 2):S111-S116.
131. Silverberg SJ and Bilezikian JP. Clinical course of primary hyperparathyroidism. In: Bilezikian JP, Marcus R, Levine MA eds. The Parathyroids, 2nd edition, 2001. San Diego, Academic Press, 387-398.
132. Solomon BL, Schaaf M, Smallridge RC: Psychologic symptoms before and after parathyroid surgery. Am J Med 1994;96:101-106.
133. Roman S, Sosa JA. Psychiatric and cognitive aspects of primary hyperparathyroidism. Curr Opin Oncol 2007;19:1-5.
134. Brown GG, Preisman RC, Kleerekoper M. Neurobehavioral symptoms in mild primary hyperparathyroidism: related to hypercalcemia but not improved by parathyroidectomy. Henry Ford Hosp Med J 1987;35:211-215.
135. Burney RE, Jones KR, Christy B, Thompson NW. Health status improvement after surgical correction of primary hyperparathyroidism in patients with high and low preoperative calcium levels. Surgery 1999;125:608-614.
136. Caillard C, Sebag F, Mathonnet M et al. Prospective evaluation of quality of life (SF-36v2) and nonspecific symptoms before and after cure of primary hyperparathyroidism (1-year follow-up). Surgery 2007;141:153-159.
137. Dotzenrath CM, Kaetsch AK, Pfingsten H et al. Neuropsychiatric and Cognitive Changes after Surgery for Primary Hyperparathyroidism. World J Surg 2006;5:680-685.
138. Pasieka JL, Parsons LL. Prospective surgical outcome study of relief of symptoms following surgery in patients with primary hyperparathyroidism. World J Surg 1998;22:513-518.
139. Prager G, Kalaschek A, Kaczirek K et al. Parathyroidectomy improves concentration and retentiveness in patients with primary hyperparathyroidism. Surgery 2002;132:930-935.
140. Roman SA, Sosa JA, Mayes L et al. Parathyroidectomy improves neurocognitive deficits in patients with primary hyperparathyroidism. Surgery 2005;138:1121-1128.
141. Pasieka JL, Parsons LL, Demeure MJ et al. Patient-based surgical outcome tool demonstrating alleviation of symptoms following parathyroidectomy in patients with primary hyperparathyroidism. World J Surg 2002;26:942-949.
142. Sheldon DG, Lee FT, Neil NJ, Ryan JA Jr .Surgical treatment of hyperparathyroidism improves health-related quality of life. Arch Surg. 2002;137:1022-1026
143. Quiros RM, Alef MJ, Wilhelm SM et al. Health-related quality of life in hyperparathyroidism measurably improves after parathyroidectomy. Surgery 2003;134:675-681.
144. Chiang CY, Andrewes DG, Anderson D, Devere M, Schweitzer I, Zajac JD. A controlled prospective study of neuropsychological outcomes post parathyoridectomy in PHPT. Clin Endocrinol 2005;62:99-104.
145. Goyal A, Chumber S, Tandon N, Lal R, Srivastava A, Gupta S. Neuropsychiatric manifestations in patients of primary hyperthyroidism and outcome following surgery. Indian J Med Sci2001;55:677-686.
146. Coker LH, Rorie K, Cantley L et al. Primary hyperparathyroidism, cognition and health related quality of life. Ann Surg 2005;242:642-648.
147. Rao DS, Philips ER, Divind GW, Talpos GB. Randomized controlled clinical trial of surgery vs no surgery in patients with mild PHPT. J Clin Endocrinol Metab 2004;89:5415-5422.
148. Bollerslev J, Jansson S, Mollerup CL et al. Medical observation, compared with parathyroidectomy, for asymptomatic primary hyperparathyroidism: a prospective, randomized trial. J Clin Endocrinol Metab 2007;92:1687-1692.
149. Ambrogini E, Cetani F, Cianferotti L et al. Surgery or surveillance for mild asymptomatic primary hyperparathyroidism: a prospective, randomized clinical trial. J Clin Endocrinol Metab. 2007;92 :3114-3121
150. Walker, MD, McMahon DK, Inabnet WB et al. Neuropsychological features in primary hyperparathyroidism: a prospective study. J. Clin Endocrinol Metab  2009;94:1951-8.
151. Walker MD, Silverberg SJ.. Parathyroidectomy in asymptomatic primary hyperparathyroidism: improves “bones” but not “psychic moans.” J Clin Endocrnol Metab 2007;92:1613-1615.
152. Roman SA, Sosa JA, Pietrzak RH, Snyder PJ, Thomas DC, Udelsman R, Mayes L. The effects of serum calcium and parathyroid hormone changes on psychological and cognitive function in patients undergoing parathyroidectomy for primary hyperparathyroidism. 2011;Ann Surg 253:131-137.
153. Bilezikian JP, Meng X, Shi Y, Silverberg SJ: Primary hyperparathyroidism in women: New York and Beijing (A Tale of Two Cities). Int'l J Fertility and Women’s Health 2000;45:158-165.
154 Mithal A, Bandeira F, Meng X, Silverberg S, Shi Y, Mishra SK, Griz L, Macedo G, Celdas G, Bandeira C, Bilezikian JP, Rao DS: Primary hyperparathyroidism in India, Brazil and China. In: The Parathyroids, 2nd Edition (Bilezikian JP, Marcus R, Levine MA, eds), Academic Press, San Diego, CA 2001,375-386.
155. Lumb GA, Stanbury SW. Parathyroid function in vitamin D deficiency in primary hyperparathyroidism. Am J Med 1974;54:833-839.
156. Silverberg SJ, Shane E, Dempster DW, Bilezikian JP. Vitamin D deficiency in primary hyperparathyroidism. Am J Med 1999;107:561-567.
157. Grey A, Lucas J, Horne A, Gamble G, Davidson JS, Reid I. Vitamin D repletion in patients with primary hyperparathyroidism and coexistent vitamin D deficiency. J Clin Endocrinol Metab. 2005;90:2122-2126.
158. Amstrup AK, Rejnmark L, Vestergaard P, Sikjaer T, Rolighed L, Heickendorff L, Mosekilde L. Vitamin D status, physical performance and body mass in patients surgically cured for primary hyperparathyroidism compared with healthy controls- a cross-sectional study. Clin Endocrinol (oxf) 2011;74:130-136.
159. Stein EM, Dempster DW, Udesky J, Zhou H, Bilezikian JP, Shane E, Silverberg SJ. Vitamin D deficiency influences histomorphometric features of bone in primary hyperparathyroidism. Bone 2011;48:557-561.
160. Nainby-Luxmoore JC, Langford HG et al. A case-comparison study of hypertension and hyperparathyroidism. J Clin Endocrinol Metab 1982;55:303-306.
161. Ringe JD Reversible hypertension in primary hyperparathyroidism--pre- and posteroperative blood pressure in 75 cases. Klin Wochenschr 1984;62:465-469.
162. Farahnak P, Ring M, Caldahl K, Farnebo LO, Eriksson MJ, Nilsson IL. Cardiac function in mild primary hyperparathyroidism and the outcome after parathyroidectomy. Eur J Endocrinol 2010;163:461-467.
163. Roberts WC, Waller BF. Effect of chronic hypercalcemia on the heart. An analysis of 18 necropsy patients. Am J Med 1981;71:371-384.
164. Iwata S, Walker MD, Di Tullio MR, Hyodo E, Jin Z, Liu R, Sacco RL, Homma S, Silverberg SJ. Aortic valve calcification in mild primary hyperparathyroidism. J Clin Endocrinol Metab 2012; 97: 132-137.
165. Walker MD and Silverberg SJ. Cardiovascular aspects of primary hyperparathyroidism. J Endocrinol Investig 2008;31:925-931.
166. Nuzzo V, Tauchmanova L, Fonderico F et al. Increased intima-media thickness of the carotid artery wall, normal blood pressure profile and normal left ventricular mass in subjects with primary hyperparathyroidism. Eur J Endocrinol 2002;147:453-459.
167. Nilsson IL, Aberg J, Rastad J, Lind L. Left ventricular systolic and diastolic function and exercise testing in primary hyperparathyroidism-effects of parathyroidectomy. Surgery 2000;128:895-902.
168. Piovesan A, Molineri N, Casasso F et al. Left ventricular hypertrophy in primary hyperparathyroidism. Effects of successful parathyroidectomy. Clin Endocrinol (Oxf) 1999;50:321-328.
169. Almqvist EG, Bondeson AG, Bondeson L et al. Cardiac dysfunction in mild primary hyperparathyroidism assessed by radionuclide angiography and echocardiography before and after parathyroidectomy. Surgery 2002;132:1126-1132
170. Stefenelli T, Abela C, Frank H et al. Cardiac abnormalities in patients with primary hyperparathyroidism: implications for follow-up. J Clin Endocrinol Metab 1997;82:106-112.
171. Persson A, Bollerslev J, Rosen T et al. Effect of surgery on cardiac structure and function in mild primary hyperparathyroidism. Clin Endocrinol (Oxf) 2011;74:174-180.
172. Ishay A, Here P, Luboshitzky R. Effects of successful parathyroidectomy on metabolic cardiovascular risk factors in patients with severe primary hyperparathyroidism. Endocr Pract 2011;16:1-19.
173. Rubin MR, Rundek T, McMahon DJ, Lee HS, Sacco RL, Silverberg SJ. Carotid artery plaque thickness is associated with increased serum calcium levels. Atherosclerosis 2007;194:426-432.
174. Walker M, Fleischer J, DiTullio MR et al. Cardiac structure and diastolic function in mild primary hyperparathyroidism. J Clin Endocrinol Metab 2010;95:2172-2179.
175. Lumachi F, Ermani M, Frego M et al. Intima-media thickness measurement of the carotid artery in patients with primary hyperparathyroidism. A prospective case-control study and long-term follow-up. In Vivo 2006;20:887-890.
176. Baykan M, Erem C, Erdogan T et al. Assessment of left ventricular diastolic function and the Tei index by tissue Doppler imaging in patients with primary hyperparathyroidism. Clin Endocrinol (Oxf) 2007;66:483-488.
177. Walker, MD, Carotid vascular abnormalities in primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 2009;94:3849-56.
178. Baykan M, Erem C, Erdogan T et al. Impairment of flow mediated vasodilatation of brachial artery in patients with primary hyperparathyroidism. Int J Cardiovasc Imaging 2007;23;323-328.
179. Smith JC, Page MD, John R et al. Augmentation of central arterial pressure in mild primary hyperparathyroidism. J Clin Endocrinol Metab 2000;85:3515-3519.
180. Rubin MR, Maurer MS, McMahon DJ, Bilezikian JP, Silverberg SJ. Arterial stiffness in mild primary hyperparathyroidism. J Clin Endocrinol Metab 2005;90;3326-3330.
181. Wajngot A, Werner S, Granberg PO, Lindvall N: Occurrence of pituitary adenomas and other neoplastic diseases in primary hyperparathyroidism. Surg Gynecol Obstet 1980;151:401-403.
182. Farr HW, Fahey TJ, Jr. Nash AG, Farr CM: Primary hyperparathyroidism and cancer. Am J Surg 1973;126:539-543.
183. Attie JN, Vardhan R: Association of hyperparathyroidism with nonmedullary thyroid carcinoma: Review of 31 cases. Head Neck 1993;15:20-23.
184. Kambouris AA, Ansari MR, Talpos GT: Primary hyperparathyroidism and associated neoplasms. Henry Ford Med J 1987;35:207-210.
185. Wermers RA, Khosla S, Atkinson EJ, Grant CS, Hodgson SF, O’Fallon M, Melton LJ: Survival after the diagnosis of hyperparathyroidism. Am J Med 1998;104:115-122.
186. Hedback G, Oden A: Increased risk of death from primary hyperparathyroidism – an update. Eur J Clin Invest 1998;28:271-276.
187. Nilsson IL et al. Clinical presentation of PHPT in Europe-nationwide cohort analysis on mortality from nonmalignant causes. J Bone Miner Res 2002;17(Suppl2): N68-N74.
188. Hedback G, Oden A, Tisell L-E: Parathyroid adenoma weight and the risk of death after treatment for primary hyperparathyroidism. Surgery 1995;117:134-139.
189. Yu N, Donnan PT, Flynn RW, et al. Increased mortality and morbidity in mild primary hyperparathyroid patients. The Parathyroid Epidemiology and Audit Research Study (PEARS). Clin Endocrinol (Oxf) 2010;73:30-4.
190. Bilezikian JP, Brandi ML, Rubin M, Silverberg SJ: Primary hyperparathyroidism: new concepts in clinical, densitometric, and biochemical features. J Int Med, 2005;257:6-17.
191. Bilezikian JP, Silverberg SJ: Management of asymptomatic primary hyperparathyroidism. N Eng J Med 2004;350:1746-1751.
192. Bilezikian JP, Silverberg SJ: Primary hyperparathyroidism. In: Primer on the Metabolic Bone Diseases and Disorders of Calcium Metabolism, 7th Edition (Rosen CJ, editor) Am Soc Bone Min Research 2008;302-306.
193 Silverberg SJ, Bilezikian JP: The diagnosis and management of asymptomatic primary hyperparathyroidism. Nature Clinical Practice Endocrinology and Metabolism 2006;2:494-503.
194 Bilezikian JP, Silverberg SJ, Rubin M, Potts, Jr. JT: Asymptomatic primary hyperparathyroidism: present management and future options. IN: Clinical Cases in Bone and Mineral Metabolism 2006;3:132-140.
195. Consensus Development Conference Panel. Diagnosis and management of asymptomatic primary hyperparathyroidism: Consensus Development Conference Statement. Ann Intern Med 1991;114:593-597.
196. Bilezikian JP, Potts JT, El-Hajj Fuleihan G, Kleerekoper M, Neer R, Peacock M, Rastad J, Silverberg SJ, Udelsman R, Wells SA: Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century. J Bone Min Res 2002;17 (Suppl 2) N2-N11; J Clin Endocrinol Metab 2002;87:5353-5361.
197. Yu N, Leese GP, Smith D, Donnan PT. The natural history of treated and untreated primary hyperparathyroidism: the parathyroid epidemiology and audit research study. QJM 2011 January 25 [Epub ahead of print: PMID 21266486]
198. Wells SA, DeBenedetti MK, Doherty GM. Surgery for recurrent or persistent hyperparathyroidism. J Bone Min Res 2002;17 (Suppl 2):N158-N162.
199. Wells SA Jr and Doherty GM. The surgical management of hyperparathyroidism. In: Bilezikian JP, Marcus R, Levine MA (eds) The Parathyroids, 2nd Edition, San Diego, Academic Press, 2001, 487-498
200. Ogilvie JB and Clark OH. Parathyroid surgery: we still need traditional and selective approaches. J Endocrinol Invest 2005;28:566-569.
201. Miccoli P. Parathyroid surgery; we only need a minimal surgical approach. J Endocrinolog Invest 2005;28:570-573.
202. Sosa JA, Udelsman R. Minimally invasive parathyroidectomy. Surg Oncol 2003;12:125-134.
203. Udelsman R, Lin Z, Donovan P. The superiority of minimally invasive parathyroidectomy based on 1650 consecutive patients with primary hyperparathyroidism. Ann Surg 2011’253;585-591.
204. Irvin GL III et al. Improved success rate in reoprative parathyroidectomy with intraoperative PTH assay. Ann Surg 1999;229:874-878.
205. Chen H et al. Intraoperative parathyroid hormone testing improves cure rates in patients undergoing minimally invasive parathyroidectomy. Surgery 2005;138:583-587.
206. Udelsman R. One hundred consecutive minimally invasive parathyroid explorations. Arch Surg 2000;31:1074-1078.
207. Udelsman R. Surgery in primary hyperparathyroidism: the patient without previous neck surgery. J Bone Min Res 2002;17(Suppl 2) N126-132.. 
208. Norton JA. Surgical management of hyperparathyroidism. In Endocrinology, 5th ed (DeGroot LJ and Jameson JL eds). WB Saunders, Philadelphia. 2006:1583-1594
209. Wells SA Jr et al. Long term-evaluation of patients with primary parathyroid hyperplasia managed by total parathyroidectomy and hetertopic autotransplantation. Ann Surg 1980;192:451-458.
210. Carling T. Udelsman R. Parathyroid surgery in familial hyperparathyroid disorders. J Inter Med 2005;257:27-37.
211. Cohen MS, Dilley WG, Wells SA, Moley JF, Doherty GM, Sicard GA, Skinner MA, Norton JA, DeBenedetti MK, Lairmore TC. Long-term functionality of cryopreserved parathyroid autograts: 1 13-year prospective analysis. Surgery 2005;138:1033-1040
212. Khan AA, Hanley DA, O’Brien CJ et al. Asymptomatic Primary Hyperparathyroidism – Standards and Guidelines for Diagnosis and Management in Canada.  Endoc Pract. 2003;9:400-405
213. Augustine MM, Bravo PE, Zeiger MA. Treatment of primary hyperparathyroidism. Endocr Pract 2011;16:1-23..
214. Civelek A, Ozalp E, Donovan P, Udelsman R. Prospective evaluation of delayed technetium-99M sestamibi SPECT scintigraphy for preoperative localization of primary hyperparathyroidism. Surgery 2002;131:149-157.
215. Van Husen R, Kim LT Accuracy of surgeon-performed ultrasound in parathyroid localization. World Journal of Surgery. 2005;281122-1126.
216. Mortenson ME, Evans DB, Hunter GJ et al. Parathyroid exploration in the reoperative neck: improved preoperative localization with 4D-computer tomography. J Am Coll Surg 2008;206:888-895.  
217. Johnson NA, Tublin ME, Ogilvie JB. Parathyroid imaging: technique and role in preoperative evaluation of primary hyperparathyroidism. Head and Neck Imaging 2007;188:1706-1715.
218. Udelsman R, Donovan PI. Remedial parathyroid surgery: changing trends in 130 consecutive cases. Ann Surg 2006;244:471-479.
219. Scholz DA, Purnell DC. Asymptomatic primary hyperparathyroidism. 10-year prospective study. Mayo Clin Proc 1981;56:473-478
220. Parisien M, Dempster DW, Shane E, Bilezikian JP: Histomorphometric analysis of bone in primary hyperparathyroidism. In: The Parathyroids, 2nd Edition (Bilezikian JP, Marcus R, Levine M, eds) Academic Press, San Diego, CA 2001;423-436.
221. Seibel MJ, Gartenberg F, Silverberg SJ, et al. Urinary hydroxypyridinium crosslinks of collagen in primary hyperparathyroidism. J Clin Endocrinol Metab 1992;74:481-486.
222. Guo CY, Thomas W, Al-Dehaimi AW, Assiri AMA, Eastell R: Longitudinal changes in bone mineral density and bone turnover in women with primary hyperparathyroidism. J Clin Endocrinol Metab 1996;81:3487-3491.
223. Tanaka Y, Funahashi H, Imai T, Tominga Y, Takagi H: Parathyroid function and bone metabolic markers in primary and secondary hyperparathyroidism. Semin Surg Oncol 1997;13:125-133.
224. Minisola S, Romagnoli E, Scarnecchia L, et al. Serum CITP in patients with primary hyperparathyroidism: Studies in basal conditions and after parathyroid surgery. Eur J Endocrinol 1994;130:587-591.
225. Fuleihan GEH, Moore F Jr, LeBoff MS, Hurwitz S, Gundberg CM, Angell J, Scott J: Longitudinal changes in bone density in hyperparathyroidism. J Clin Densitometry 1999;2:153-162.
226. Almqvist EG, Becker C, Bondeson AG, Bondeson L, Svensson J. Early parathyroidectomy increases bone mineral density in patients with mild primary hyperparathyroidism: a prospective and randomized study. Surgery 2004;136(6):1281-8.
227. Kulak CAM, Bandeira C, Voss D, Sobieszczyk SM, Bandeira F, Silverberg SJ, Bilezikian JP. Marked improvement in bone mass after parathyroidectomy in osteitis fibros cystica.J Clin Endocrinol 1998;83:732-735.
228. Deaconson TF, Wilson SD, Lemann J: The effect of parathyroidectomy on the recurrence of nephrolithiasis. Surgery 1987;215:241-251.
229. Kaplan RA, Snyder WH, Stewart A, et al. Metabolic effects of parathyroidectomy in asymptomatic primary hyperparathyroidism. J Clin Endocrinol Metab 1976;42:415-426.
230. Lewiecki EM. Management of skeletal health in patients with asymptomatic primary hyperparathyroidism. J Clin Densitom 2010;12:324-334.
231. Stock JL and Marcus R.  Medical management of primary hyperparathyroidism.  In: Bilezikian JP, Marcus R, Levine MA eds. The Parathyroids, 2nd edition, 2001. San Diego, Academic Press, 459-474.
232. Locker FG, Silverberg SJ, Bilezikian JP.  Optimal dietary calcium intake in primary hyperparathyroidism.  Am J Medicine 1997;102: 543-550
233. Marcus R, Madvig P, Crim M, Pont A, Kosek J:  Conjugated estrogens in the treatment of postmenopausal women with hyperparathyroidism.  Ann Intern Med  1984;100:633-640.
234. Selby PL, Peacock M:  Ethinyl estradiol and norethinedrone in the treatment of primary hyperparathyroidism in postmenopausal women.  N Engl J Med 1986;314:1481-1485.
235. Grey AB, Stapleton JP, Evans MC, Tatnell MA, Reid IR.  Effect of hormone replacement therapy on BMD in post-menopausal women with primary hyperparathyroidism.  Ann Int Med 1996;125: 360-368.
236. Writing group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women’s Health Initiative Randomized Controlled Trial. J Am Med Assoc 2002;228:321-333.
237. Marcus R. The role of estrogen and related compounds in the management of primary hyperparathyroidism. J Bone Miner Res 2002;17 (Suppl. 2): N146-N149.
238. Rubin MR, Lee K, McMahon DJ, Silverberg SJ. Raloxifene lowers serum calcium  and markers of bone turnover in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab 2003;88:1174-1178
239. Zanchetta JR and Bogado CE. Raloxifene reverses bone loss in postmenopausal women with mild asymptomatic primary hyperparathyroidism. J Bone Miner Res 2001;16:189-190.
240. Silverberg SJ, Bilezikian JP: Primary hyperparathyroidism. IN: Dynamics of Bone and Cartilage Metabolism (Seibel MJ, Robins SP, Bilezikian JP, eds) Elsevier Press, San Diego, CA, 2006;767-778.
241. Kaplan RA, Geho WB, Poindexter C, Haussler M, Dietz GW, Pak CYC. Metabolic effects of diphosphonate in primary hyperparathyroidism. J Clin Pharmacol. 1977;17:410-419.
242. Shane E, Baquiran DC, Bilezikian JP. Effects of dichloromethylene diphosphonate on serum and urinary calcium in primary hyperparathyroidism. Ann Int Med 1981;95:23-27.
243. Reasner CA, Stone MD, Hosking DJ, Ballah A, Mundy GR. Acute changes in calcium homeostasis during treatment of primary hyperparathyroidism with risedronate. J Clin Endocrinol Metab 1993;77:1067-1071.
244. Rossini M, Gatti D, Isaia G, Sartori L, Braga V, Adami S Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism.  2001;16:113-119.
245. Hassani S, Braunstein GD, Seibel MJ, Brickman AS, Geola F, Pekay AE, Hershman JM. Alendronate therapy of primary hyperparathyroidism. The Endocrinologist. 2001;11:459-464.
246. Parker CR, Blackwell PJ, Fairbairn KJ, Hosking DJ. Alendronate in the treatment of primary hyperparathyroid-related osteoporosis: J Clin Endocrinol Metab 2002;87:4482-4489.
247. Chow CC, Chan WB, Li JKY, Chan NN, Chan MH, Ko GTC, Lo KW, Cockram CS. Oral Alendronate increases bone mineral density in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab 2003;88:581-587.
248. Khan AA, Bilezikian JP, Kung AWC, Ahmed MM, Dubois SJ, Ho AYY, Schussheim D, Rubin MR, Shaikh AM, Silverberg SJ, Standish TI, Syed Z, Syed ZA: Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial. J Clin Endocrinol Metab 2004;89:3319-3325.
249. Khan AA, Bilezikian JPO, Kung A, Syed ZA, Dubois SJ, Standish TI. Alendronate in men with primary hyperparathyroidism. Endocr Pract 2009;15:705-713.
250. Marcocci C, Cianferotti L, Silverberg SJ, Bilezikian JP. Primary hyperparathyroidism in men. In: Osteoporosis in Men (Orwoll E, Bilezikian JP, Vanderscheuren D, eds). Elsevier, San Diego, 2010;465-478.
251. Steffey ME, Fox J, Van Wagenen BC, DelMar EG, Balandrin MF, Nemeth EF.  Calcimimetics: structurally and mechanistically novel compounds that inhibit hormone secretion from parathyroid cells.  J Bone Mineral Res; 1993;8: s17.
252. Silverberg SJ, Marriott TB, Bone lll HG, Locker FG, Thys-Jacobs S, Dziem G, Sanguinetti ES,  Bilezikian JP.  Short term inhibition of parathyroid hormone secretion by a calcium receptor agonist in primary hyperparathyroidism.  N Engl J Med 1997;307:1506-1510.
253. Locatelli F, Pontoriero G, Limardo M, Tentori F. Cinacalcet hydrochloride: calcimimetic for the treatment of hyperparathyroidism. Expert Rev Endocrinol Metab 2006;1:167-179.
254. Messa P, Alfieri C, Brezzi B. Clinical utilization of cinacalcet in hypercalcemic conditions. Expert Opin Drug Metab Toxicol 2011, March ([Epub ahead of print, PMID: 21361849]
255. Shoback DM, Bilezikian JP, Turner SA, McCary LC, Guo MD, Peacock M: The calcimimetic AMG 073 normalizes serum calcium in patients with primary hyperparathyroidism. J Clin Endocrinol Metab 2003;88:5644-5649.
256. Peacock M, Bilezikian JP, Klassen PS, Guo MD, Turner SA, Shoback DM: Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. J Clin Endocrinol Metab 2005;90:135-141.
257. Peacock M, Bolognese MA, Borofsky M et al. Cinacalcet treatment of primary hyperparathyroidism: biochemical and bone densitometric outcomes in a five-year study. J. Clin. Endocrinol. Metab. 2009;94, 4860-4867..
258. Peacock M, Bilezikian JP, Bolognese MA et al. Cinacalcet HCl reduces hypercalcemia in primary hyperparathyroidism across a wide spectrum of disease severity. J Clin Endocrinol Metab 2011;96:E9-E18.
259. Marcocci C, Chanson P, Shoback D, Bilezikian JP, Fernandez-Cruz L, Orgiazzi J, et al. Cinacalcet reduces serum calcium concentrations in patients with intractable primary hyperparathyroidism. J Clin Endocrinol Metab 2009;94;2766-2772.
260.Collins MT, Skarulis MC, Bilezikian JP, Silverberg SJ, Spiegel AM, Marx SJ: Treatment of hypercalcemia secondary to parathyroid carcinoma with a novel calcimimetic agent. J Clin Endocrinol Metab 1998;83:1083-1088.
261. Rubin MR, Sliney J, Silverberg SJ, Bilezikian JP: Clinical course of 10 patients with inoperable parathyroid carcinoma treated with the calcimimetic cinacalcet HCI. J Bone Min Res 2004;19 (Suppl 1) S103.
262. Silverberg SJ, Rubin MR, Faiman C, Peacock M, Shoback DM, Smallridge R, Schwanauer LE, Olson KA, Turner SA, Bilezikian JP: Cinacalcet HCI effectively reduces the serum calcium concentration in parathyroid carcinoma. J Clin Endocrinol Metab 2007;92:3802-3808.
263. Marcocci C, Cetani F, Rubin MR, Silverberg SJ, Pinchera A, Bilezikian JP. Parathyroid cancer. J Bone Min Res 23:2008;1869-1880.